<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Surg Neurol Int</journal-id><journal-id journal-id-type="iso-abbrev">Surg Neurol Int</journal-id><journal-id journal-id-type="pmc-domain-id">1278</journal-id><journal-id journal-id-type="pmc-domain">sni</journal-id><journal-title-group><journal-title>Surgical Neurology International</journal-title></journal-title-group><issn pub-type="ppub">2229-5097</issn><issn pub-type="epub">2152-7806</issn><publisher><publisher-name>Scientific Scholar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10316227</article-id><article-id pub-id-type="pmcid-ver">PMC10316227.1</article-id><article-id pub-id-type="pmcaid">10316227</article-id><article-id pub-id-type="pmcaiid">10316227</article-id><article-id pub-id-type="pmid">37404508</article-id><article-id pub-id-type="doi">10.25259/SNI_1051_2022</article-id><article-id pub-id-type="publisher-id">10.25259/SNI_1051_2022</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Middle meningeal artery embolization for symptomatic chronic subdural hematoma in the setting of severe transfusion-refractory thrombocytopenia: A case study and review of literature</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Morden</surname><given-names initials="FTC">Frances Tiffany Cava</given-names></name><xref rid="cor1" ref-type="corresp"/><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmorden@hawaii.edu">fmorden@hawaii.edu</email><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-2520-3333" ext-link-type="uri">https://orcid.org/0000-0003-2520-3333</ext-link></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caballero</surname><given-names initials="CG">Clark Gianni</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cgbc@hawaii.edu">cgbc@hawaii.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abella</surname><given-names initials="M">Maveric</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="maveric@hawaii.edu">maveric@hawaii.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Conching</surname><given-names initials="A">Andie</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="andiec@hawaii.edu">andiec@hawaii.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gang</surname><given-names initials="H">Hannah</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hannahgang2003@gmail.com">hannahgang2003@gmail.com</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noh</surname><given-names initials="T">Thomas</given-names></name><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="thomas.noh@gmail.com">thomas.noh@gmail.com</email><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-6171-8492" ext-link-type="uri">https://orcid.org/0000-0002-6171-8492</ext-link></contrib></contrib-group><aff id="aff1">Division of Neurological Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, United States.</aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> Frances Tiffany Cava Morden, Division of Neurological Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, United States. <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fmorden@hawaii.edu">fmorden@hawaii.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>30</day><month>6</month><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">428220</issue-id><elocation-id>223</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>04</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-05 17:25:10.127"><day>05</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2023 Surgical Neurology International</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="SNI-14-223.pdf"/><abstract><sec id="st1"><title>Background: </title><p>Surgical decompression for the treatment of chronic subdural hematomas (cSDHs) is irrefutably effective; however, its utility in managing cSDH in patients with comorbid coagulopathy remains controversial. The optimal threshold for platelet transfusion in cSDH management is &lt;100,000/mm<sup>3</sup>, according to guidelines from the American Association of Blood Banks GRADE framework. This threshold may be unachievable in refractory thrombocytopenia, though surgical intervention may still be warranted. We present a patient with symptomatic cSDH and transfusion-refractory thrombocytopenia successfully treated with middle meningeal artery embolization (eMMA). We also review the literature to identify management approaches for cSDH with severe thrombocytopenia.</p></sec><sec id="st2"><title>Case Description: </title><p>A 74-year-old male with acute myeloid leukemia presented to the emergency department with persistent headache and emesis following fall without head trauma. Computed tomography (CT) revealed a 12 mm right-sided, mixed density SDH. Platelets were &lt;2000/mm<sup>3</sup> initially, which stabilized to 20,000 following platelet transfusions. He then underwent right eMMA without surgical evacuation. He received intermittent platelet transfusions with platelet goal &gt;20,000 and was discharged on hospital day 24 with resolving SDH on CT.</p></sec><sec id="st3"><title>Conclusion: </title><p>High-risk surgical patients with refractory thrombocytopenia and symptomatic cSDH may be successfully treated with eMMA without surgical evacuation. A platelet goal of 20,000/mm<sup>3</sup> before and following surgical intervention proved beneficial for our patient. Similarly, a literature review of seven cases of cSDH with comorbid thrombocytopenia revealed five patients undergoing surgical evacuation following initial medical management. Three cases reported a platelet goal of 20,000. All seven cases resulted in stable or resolving SDH with platelets &gt;20,000 at discharge.</p></sec></abstract><kwd-group><kwd>Chronic subdural hematoma</kwd><kwd>Middle meningeal artery embolization</kwd><kwd>Platelet goal</kwd><kwd>Platelet transfusion</kwd><kwd>Thrombocytopenia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="SNI-14-223-inline001.jpg"/>
</p><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Chronic subdural hematoma (cSDH) is a common complication of acute myeloid leukemia (AML).[<xref rid="ref20" ref-type="bibr">20</xref>] The incidence of cSDH is estimated to be 1.7&#8211;20.6 patients/100,000 patients/year and commonly presents with cognitive and behavioral symptoms.[<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref30" ref-type="bibr">30</xref>,<xref rid="ref35" ref-type="bibr">35</xref>] The most common treatment for cSDH for patients is surgical drainage with burr hole trephination, craniotomy, and decompressive craniectomy.[<xref rid="ref6" ref-type="bibr">6</xref>] However, 5&#8211;30% of cases will experience recurrence of their hematoma,[<xref rid="ref7" ref-type="bibr">7</xref>] and one of the factors that increase the risk of recurrence is comorbid coagulopathy, such as in patients with leukemia.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Treatments for acute myeloid leukemia (AML) like chemotherapy and hypomethylating agents put patients at increased risk for thrombocytopenia and intracranial hemorrhage,[<xref rid="ref15" ref-type="bibr">15</xref>] and, the mainstay of treatment for thrombocytopenia continues to be platelet transfusions.[<xref rid="ref11" ref-type="bibr">11</xref>] Increased risk for spontaneous bleeding occurs with platelet counts &lt;20,000/&#181;L, and a threshold platelet count of &gt;10,000/ &#181;L is recommended for prophylactic platelet transfusion in patients receiving therapy for hematologic malignancies.[<xref rid="ref26" ref-type="bibr">26</xref>,<xref rid="ref36" ref-type="bibr">36</xref>] Higher platelet counts of &gt;20,000/&#181;L are recommended in the setting of hemorrhage as well as in settings of expectant invasive procedures.[<xref rid="ref36" ref-type="bibr">36</xref>] Threshold platelet counts 40&#8211;50,000/&#181;L are recommended before performing any major invasive procedure and platelet counts &gt;100,000/&#181;L before neurosurgery.[<xref rid="ref36" ref-type="bibr">36</xref>] According to the World Health Organization, nonfatal cerebral bleeding with neurological signs and symptoms is considered Grade 4 bleeding with a recommended maintenance platelet goal of 100,000/&#181;L.[<xref rid="ref11" ref-type="bibr">11</xref>] However, there are limited evidence-based recommendations in cases of transfusion-refractory thrombocytopenia and case reports have shown patient survival at much lower platelet levels.[<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref43" ref-type="bibr">43</xref>]</p><p>Middle meningeal artery embolization (eMMA) for cSDH is an emerging treatment modality.[<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref19" ref-type="bibr">19</xref>,<xref rid="ref21" ref-type="bibr">21</xref>,<xref rid="ref27" ref-type="bibr">27</xref>,<xref rid="ref28" ref-type="bibr">28</xref>,<xref rid="ref33" ref-type="bibr">33</xref>,<xref rid="ref38" ref-type="bibr">38</xref>] The efficacy of eMMA is centered around the theory that cSDHs are, in part, caused by repeated membranous vessel rupture that is supplied by the MMA, so eMMA works by devascularizing these ruptured membranes.[<xref rid="ref13" ref-type="bibr">13</xref>] It decreases the likelihood of hematoma recurrence and can be used as the sole treatment for patients with high surgical risk. In a recent meta-analysis of nine case series, Srivatsan <italic toggle="yes">et al</italic>. demonstrated a robust effect of eMMA as a sole therapy or as an adjunct to prevent rebleeding with eMMA having significantly lower rates of hematoma recurrence compared to the conventional surgery group (2.1% vs. 27.7%; <italic toggle="yes">P</italic> &lt; 0.001).[<xref rid="ref39" ref-type="bibr">39</xref>] Moreover, this meta-analysis found the procedural complication rates to be similar between eMMA and conventional surgery (2.1% vs. 4.4%; <italic toggle="yes">P</italic> = 0.497).[<xref rid="ref39" ref-type="bibr">39</xref>] Two of the largest case series using eMMA for the management of cSDH (Link <italic toggle="yes">et al</italic>.[<xref rid="ref28" ref-type="bibr">28</xref>] and Ban <italic toggle="yes">et al</italic>.[<xref rid="ref4" ref-type="bibr">4</xref>]) found no complications related to eMMA. In addition, a recent meta-analysis of 54,083 cerebral angiography cases found a procedural complication rate of 3.60%.[<xref rid="ref16" ref-type="bibr">16</xref>] These complications include transient ischemic attack, ischemic stroke, contrast-induced nephropathy, and contrast-induced allergic reaction.[<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref32" ref-type="bibr">32</xref>,<xref rid="ref37" ref-type="bibr">37</xref>] Several large prospective randomized trials are underway investigating patient selection and the combination of surgery and embolization.[<xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref13" ref-type="bibr">13</xref>]</p><p>To the best of our knowledge, there has been no report of a patient with AML, symptomatic cSDH, and transfusion-refractory thrombocytopenia treated with eMMA. We present a case of improving chronic SDH in the setting of AML-related thrombocytopenia by eMMA without surgical evacuation. We also performed a systematic review of the literature to identify management strategies for cSDH with severe thrombocytopenia.</p></sec><sec sec-type="cases" id="sec1-2"><title>CASE PRESENTATION</title><p>A 74-year-old man with a history of AML presented to the emergency department (ED) for a complaint of nonresolving throbbing headache with nausea and vomiting after a witnessed fall without head trauma. He was on his second cycle of therapy with venetoclax and a hypomethylating agent.</p><p>At presentation to the ED, he had left upper extremity and left lower extremity drift with 4/5 left upper and lower extremity weakness, and scattered ecchymoses with a petechial rash. Laboratory studies were significant for severe thrombocytopenia of &lt;2000/&#181;L in the ED. Computed tomography of the head (hCT) revealed a right sided, mixed density 12 mm SDH with a 12 mm leftward midline shift and patchy acute subarachnoid hemorrhages [<xref rid="F1" ref-type="fig">Figure 1a</xref>]. The patient received an initial infusion of 2 units of platelets with an increase to 11,000/&#181;L. Neurosurgery was consulted and patient was subsequently admitted to the intensive care unit (ICU) with a platelet goal of 100,000/ &#181;L. Patient received regular platelet transfusions; however, platelet levels remained &lt;50,000/&#181;L [<xref rid="T1" ref-type="table">Table 1</xref>]. Given his refractory thrombocytopenia, neurologically intact status, and stable SDH on repeat hCT; conservative management was chosen over neurosurgical intervention. On hospital day 4, he was transferred out of the ICU and liberalized to a platelet goal of 50,000/&#181;L and transfusion threshold of 40,000/&#181;L. After receiving a total of 17 units of platelets, the patient underwent right eMMA with 150 &#181;m of polyvinyl alcohol particles on hospital day 8 [<xref rid="F1" ref-type="fig">Figure 1b</xref>]. Repeat hCT on hospital day 17 demonstrated a decreasing SDH [<xref rid="F1" ref-type="fig">Figure 1c</xref>]. Patient received an additional 6 units of platelets for refractory thrombocytopenia, a course of levetiracetam for seizure prophylaxis and was discharged 24 days after admission with a platelet count of 19,200/&#181;L. Discharge plans included a systolic blood pressure goal of &lt;140 mmHg and a platelet count goal &gt;10,000/&#181;L. He continued to have platelet transfusions 3 times a week with an average platelet count of 14,000/&#181;L [<xref rid="F2" ref-type="fig">Figure 2</xref>]. A hCT 30 days after discharge demonstrated a stable, panhemispheric acute on chronic SDH that was 15 mm in size with a 5 mm leftward midline shift [<xref rid="F3" ref-type="fig">Figure 3</xref>].</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><p>Evolution of subdural hematoma (SDH) from presentation to 45 days later via head computed tomography (CT). (a) Head CT at initial presentation revealed a right-sided, mixed density 12 mm SDH with 12 mm midline shift to the left. (b) Cerebral angiogram visualizing middle meningeal artery. (c) Repeat head CT on hospital day 17 showing stable right SDH with resolving midline shift (5 mm to left).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-g001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2:</label><caption><p>Graphical depiction of patient&#8217;s platelet counts following initial presentation. The patient&#8217;s platelet count ranged from &lt;2000/mm<sup>3</sup> at initial presentation up to 48,000 5 days after presentation following multiple platelet transfusions. He underwent eMMA 7 days after presentation with platelet count of 20,000. He was discharged on 23 days after presentation and received outpatient platelet transfusions 3 times a week with a platelet goal of 20,000. His average platelet count was 14,000.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-g002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3:</label><caption><p>Head magnetic resonance imaging 54 days after initial presentation of subdural hematoma (SDH). Sagittal and axial views of the right-sided hyperintense with patchy hypointense areas consistent with acute on chronic SDH.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-g003.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1:</label><caption><p>Summary of platelet counts and interventions throughout hospital course.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-t001.jpg"/></table-wrap><p>Fifty days after his initial presentation, the patient was readmitted for acute kidney injury secondary to severe tumor lysis syndrome, acute colitis, acute left pyelonephritis, anemia with hemoglobin of 7.8 g/dL, and thrombocytopenia with platelet count of 9000/&#181;L. On hospital day 2, hCT showed a grossly stable SDH. He was considered a poor candidate for hemodialysis due to AML, discharged to hospice on hospital day 7, and passed 4 days later.</p><sec id="sec2-2_1"><title>Systematic review</title><p>The optimal management of cSDHs in patients with concurrent thrombocytopenia remains obscure. In this review, we sought to find case reports or series similar to our patient to identify management strategies and treatment efficacy for cSDH with severe thrombocytopenia currently documented in the literature.</p><p>The preferred reporting items for systematic reviews and meta-analyses (PRISMA) reporting guideline were implemented for this review. A systematic search of PubMed and Web of Science data was conducted on October 13, 2021. The following search terms were utilized: <italic toggle="yes">thrombocytopenia</italic> OR <italic toggle="yes">pancytopenia; subdural; hematoma</italic> OR <italic toggle="yes">hemorrhage</italic> OR <italic toggle="yes">bleed*</italic>. Inclusion criteria required detection of isodense or hypodense areas in the subdural space on CT and report of individual patient data on platelet counts at intracranial cSDH confirmation, management of cSDH, platelet count following management, and outcome. Patients &lt;18 years old and patients taking anticoagulants before cSDH presentation were excluded from the study. Reviews, editorials, and non-English articles were also excluded from the study. Two independent authors assessed the articles for inclusion and exclusion criteria.</p><p>Individual patient data on the following were collected: age, sex, risk factors/etiology of thrombocytopenia, location of SDH, size of SDH, presence of midline shift, platelet counts at the time of SDH confirmation and after management, management of SDH and thrombocytopenia, platelet goal for management, complications, recurrence of SDH, and outcome at last follow-up. These data were collected by one author and reviewed by another author.</p><p>Seven out of 242 studies met inclusion criteria.[<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref17" ref-type="bibr">17</xref>,<xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref40" ref-type="bibr">40</xref>,<xref rid="ref43" ref-type="bibr">43</xref>] The PRISMA flow chart for the search strategy is depicted in [<xref rid="F4" ref-type="fig">Figure 4</xref>]. There was a total of seven patients whose data were extracted. A summary of these data is shown in [<xref rid="T2" ref-type="table">Tables 2</xref> and <xref rid="T3" ref-type="table">3</xref>]. The most common etiology of thrombocytopenia was immune thrombocytopenic purpura (ITP; 71.4%). Other etiologies included human immunodeficiency virus (14.3%) and acute lymphoblastic leukemia (ALL) (14.3%). Location of SDH was in the frontoparietal region in 4 patients (57.1%), frontotemporal in 1 (14.3%), and hemispheric in 2 (28.6%). Four patients also had a midline shift on imaging (57.1%), with the majority having a shift to the right (75%). All seven patients had severe thrombocytopenia with a platelet count &lt;5000/ &#181;L at cSDH discovery. Five patients received medical management followed by surgical evacuation (71.4%), while one patient was managed conservatively (14.3%). Surgical evacuation included partial craniotomy (1; 20%) and craniotomy evacuation (4; 80%). Three cases reported a platelet goal of 2000/&#181;L for management (42.9%). The final platelet counts were all above 20,000/&#181;L, and all cSDHs were stable or completely resolved following treatment.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4:</label><caption><p>Preferred reporting items for systematic reviews and meta-analyses flow chart of systematic review conducted in October 2021. A total of 242 unique records were identified using PubMed and Web of Science databases. Initial title and abstract screening excluded 97 articles. Full-text screening found seven articles meeting inclusion criteria, n: Number.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-g004.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2:</label><caption><p>Summary of included case reports and general characteristics of patients with cSDH.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-t002.jpg"/></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3:</label><caption><p>Summary of management, complications, and outcomes of patients with cSDH secondary to thrombocytopenia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="SNI-14-223-t003.jpg"/></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-3"><title>DISCUSSION</title><p>Previous studies on safe platelet ranges for surgical management of SDHs focused on platelet transfusions for achieving platelet goals.[<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref12" ref-type="bibr">12</xref>] However, a small subset of patients remains thrombocytopenic despite platelet transfusions. There is limited knowledge on contingent management options for these patients. This case report demonstrated the usefulness of eMMA as a minimally invasive treatment for cSDH in the setting of refractory thrombocytopenia. Each of the seven patients reported in this systematic review had final platelet counts &gt;20,000/&#181;L, and all cSDHs were stable or completely resolved following medical or surgical treatment. While current guidelines suggest a platelet count &gt;100,000/&#181;L before performing neurosurgery (level 1C evidence), there are no current platelet thresholds for patients needing surgery complicated by platelet refractoriness.[<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref34" ref-type="bibr">34</xref>]</p><p>The medical and surgical management varied widely among cases. Complications varied with two of the seven cases (Patient 1 and 4) having recurrence of the SDH after treatment. Patient 1 was diagnosed with concurrent ITP with the left-sided SDH and underwent left frontoparietal craniotomy with IV methylprednisolone and IVIG. Patient 4 had philadelphia chromosome positive ALL with bilateral SDH while receiving imatinib and dasatinib therapy and underwent trephination. Thrombocytopenia induced by hematologic disorders, such as ITP and ALL predisposed these patients to higher risk of recurrence after initial surgical management for SDH. Circulating autoantibodies due to the ITP present in Patient 1 led to a diminished recovery rate in endogenous platelet counts. ALL is known to lead to marrow failure contributing to decreased platelet count, making it difficult to recover adequate platelet numbers to prevent recurrent bleeding. This is the first report of eMMA for stabilization of cSDH without recurrence in the setting of refractory thrombocytopenia.</p><p>Once thought to be due to a singular event, the central pathology of SDHs is now being recognized as a cerebrovascular event with a cycle of hemorrhage, fibrosis, and angiogenesis.[<xref rid="ref5" ref-type="bibr">5</xref>] While the shearing of bridging veins may remain an inciting factor to the formation of a SDH, it is the inflammatory response to the extravasation of blood into the subdural space that accounts for the chronic and remittent nature of the hemorrhage.[<xref rid="ref5" ref-type="bibr">5</xref>] Mild head injury causes an insidious bleed that activates fibroblasts to migrate toward the site of the clot.[<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref18" ref-type="bibr">18</xref>] Once activated, these fibroblasts initiate fibrosis and neovascularization through the release of vascular endothelial growth factor and other pro-inflammatory signaling molecules.[<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref18" ref-type="bibr">18</xref>] These newly formed vessels are frail and prone to rebleeding, causing the cycle to repeat. While resorption of extravasated fluid may initially be maintained, eventually the rate of hemorrhage overwhelms the rate of resorption leading to increased intracranial pressure and focal neurological deficits.[<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref18" ref-type="bibr">18</xref>]</p><p>The MMA is believed to supply the outer membrane of a SDH,[<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref42" ref-type="bibr">42</xref>] and a more recent study by Mureb <italic toggle="yes">et al</italic>. proposed that the MMA contributes to not only the outer membrane but the entire hematoma complex.[<xref rid="ref31" ref-type="bibr">31</xref>] Therefore, eMMA is proposed to occlude the distal branches of the MMA decreasing the neovascularization of the hematoma. This is thought to prevent fluid leakage and shift the balance back toward resorption.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>Although the exact mechanism of eMMA remains unclear, our findings support its use in populations with persistent refractory thrombocytopenia to prevent further bleeding. In this case, the patient&#8217;s cSDH was stable enough to be managed outside the hospital, so he spent his last moments with his loved ones as per his advanced directive. The overall treatment benefit among patients with substantial disease burden should also be emphasized in the management of cSDH.</p></sec><sec sec-type="conclusions" id="sec1-4"><title>CONCLUSION</title><p>Our case has shown the success of eMMA without surgical evacuation in successfully treating symptomatic cSDH in a high-risk surgical patient with refractory thrombocytopenia. Based on this case and a systematic review of seven cases of cSDH with comorbid thrombocytopenia, a platelet goal of 20,000/mm<sup>3</sup> prior to any surgical intervention may be sufficient and more attainable than current platelet goals of 40,000-50,000/mm<sup>3</sup>. Though all patients included in this review had stable or resolving cSDH, further investigations are required to determine the utility of lowering the platelet threshold prior to neurosurgical intervention.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge Andrea Siu for facilitating the logical aspects of this study. Thank you to the medical institution for assistance with data retrieval.</p></ack><fn-group><fn id="fn1"><p><bold>How to cite this article:</bold> Morden FC, Caballero C, Abella M, Conching A, Gang H, Noh T. Middle meningeal artery embolization for symptomatic chronic subdural hematoma in the setting of severe transfusion-refractory thrombocytopenia: A case study and review of literature. Surg Neurol Int 2023;14:223.</p></fn></fn-group><sec id="sec1-5"><title>Declaration of patient consent</title><p>The authors certify that they have obtained all appropriate patient consent.</p></sec><sec sec-type="financial-disclosure" id="sec1-6"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec1-7"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelfatah</surname><given-names>M</given-names></name></person-group><article-title>Management of chronic subdural hematoma in patients with intractable thrombocytopenia</article-title><source>Turk Neurosurg</source><year>2016</year><volume>28</volume><fpage>400</fpage><lpage>4</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.5137/1019-5149.JTN.18825-16.1</pub-id><pub-id pub-id-type="pmid">27858397</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kilitci</surname><given-names>A</given-names></name><collab>Department of Pathology, Ahi Evran University School of Medicine, Kirsehir, Turkey</collab></person-group><article-title>Emergency surgical intervention to treat a wide septated subdural hematoma in a patient with ITP: A case report</article-title><source>Cyprus J Med Sci</source><year>2019</year><volume>4</volume><fpage>63</fpage><lpage>5</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balser</surname><given-names>D</given-names></name><name name-style="western"><surname>Farooq</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehmood</surname><given-names>T</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>M</given-names></name><name name-style="western"><surname>Samadani</surname><given-names>U</given-names></name></person-group><article-title>Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations</article-title><source>J Neurosurg</source><year>2015</year><volume>123</volume><fpage>1209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25794342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2014.9.JNS141550</pub-id><pub-id pub-id-type="pmcid">PMC4575892</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ban</surname><given-names>SP</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>G</given-names></name><name name-style="western"><surname>Byoun</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SU</given-names></name><name name-style="western"><surname>Bang</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Middle meningeal artery embolization for chronic subdural hematoma</article-title><source>Radiology</source><year>2018</year><volume>286</volume><fpage>992</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29019449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2017170053</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bounajem</surname><given-names>MT</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>RA</given-names></name><name name-style="western"><surname>Denorme</surname><given-names>F</given-names></name><name name-style="western"><surname>Grandhi</surname><given-names>R</given-names></name></person-group><article-title>Paradigms in chronic subdural hematoma pathophysiology: Current treatments and new directions</article-title><source>J Trauma Acute Care Surg</source><year>2021</year><volume>91</volume><fpage>e134</fpage><pub-id pub-id-type="pmid">34538825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TA.0000000000003404</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullock</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chesnut</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ghajar</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>RM</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Surgical management of acute subdural hematomas</article-title><source>Neurosurgery</source><year>2006</year><volume>58</volume><issue>3 Suppl</issue><fpage>S16</fpage><lpage>24</lpage><comment>discussion Si-iv</comment><pub-id pub-id-type="pmid">16710968</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlsen</surname><given-names>JG</given-names></name><name name-style="western"><surname>Cortnum</surname><given-names>S</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>JC</given-names></name></person-group><article-title>Recurrence of chronic subdural haematomata with and without post-operative drainage</article-title><source>Br J Neurosurg</source><year>2011</year><volume>25</volume><fpage>388</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21501053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/02688697.2011.558945</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catapano</surname><given-names>JS</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>AA</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>FC</given-names></name><name name-style="western"><surname>Ducruet</surname><given-names>AF</given-names></name></person-group><article-title>Middle meningeal artery embolization for chronic subdural hematoma</article-title><source>Front Neurol</source><year>2020</year><volume>11</volume><fpage>557233</fpage><pub-id pub-id-type="pmid">33192990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.557233</pub-id><pub-id pub-id-type="pmcid">PMC7606850</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#233;sir</surname><given-names>LL</given-names></name><name name-style="western"><surname>D&#8217;Amico</surname><given-names>R</given-names></name><name name-style="western"><surname>Link</surname><given-names>T</given-names></name><name name-style="western"><surname>Silva</surname><given-names>D</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>JA</given-names></name><name name-style="western"><surname>Doron</surname><given-names>O</given-names></name><etal/></person-group><article-title>Middle meningeal artery embolization and the treatment of a chronic subdural hematoma</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e18868</fpage><pub-id pub-id-type="pmid">34754700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.18868</pub-id><pub-id pub-id-type="pmcid">PMC8570051</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edlmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Giorgi-Coll</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitfield</surname><given-names>PC</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>KL</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>PJ</given-names></name></person-group><article-title>Pathophysiology of chronic subdural haematoma: Inflammation, angiogenesis and implications for pharmacotherapy</article-title><source>J Neuroinflammation</source><year>2017</year><volume>14</volume><fpage>108</fpage><pub-id pub-id-type="pmid">28558815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-017-0881-y</pub-id><pub-id pub-id-type="pmcid">PMC5450087</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estcourt</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Birchall</surname><given-names>J</given-names></name><name name-style="western"><surname>Allard</surname><given-names>S</given-names></name><name name-style="western"><surname>Bassey</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>P</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Guidelines for the use of platelet transfusions</article-title><source>Br J Haematol</source><year>2017</year><volume>176</volume><fpage>365</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">28009056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.14423</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estcourt</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Stanworth</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>MF</given-names></name></person-group><article-title>Platelet transfusions for patients with haematological malignancies: Who needs them?</article-title><source>Br J Haematol</source><year>2011</year><volume>154</volume><fpage>425</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">21615375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2141.2010.08483.x</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feghali</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>Updates in chronic subdural hematoma: Epidemiology, etiology, pathogenesis, treatment, and outcome</article-title><source>World Neurosurg</source><year>2020</year><volume>141</volume><fpage>339</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">32593768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2020.06.140</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorella</surname><given-names>D</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>AS</given-names></name></person-group><article-title>Middle meningeal artery embolization for the management of chronic subdural hematoma</article-title><source>J NeuroInterv Surg</source><year>2019</year><volume>11</volume><fpage>912</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">30798265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/neurintsurg-2019-014730</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e11860</fpage><pub-id pub-id-type="pmid">30142779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000011860</pub-id><pub-id pub-id-type="pmcid">PMC6112947</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaith</surname><given-names>AK</given-names></name><name name-style="western"><surname>El Naamani</surname><given-names>K</given-names></name><name name-style="western"><surname>Mualem</surname><given-names>W</given-names></name><name name-style="western"><surname>Ghanem</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajjoub</surname><given-names>R</given-names></name><name name-style="western"><surname>Sweid</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transradial versus transfemoral approaches in diagnostic and therapeutic neuroendovascular interventions: A meta-analysis of current literature</article-title><source>World Neurosurg</source><year>2022</year><volume>164</volume><fpage>e694</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">35580777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2022.05.031</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>A</given-names></name><name name-style="western"><surname>Ueoka</surname><given-names>H</given-names></name></person-group><article-title>Successful treatment of idiopathic thrombocytopenic purpura by Chinese herbal medicine EK-49 and ascorbic acid in an elderly patient developing chronic subdural hematoma</article-title><source>Geriatr Gerontol Int</source><year>2007</year><volume>7</volume><fpage>83</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3143/geriatrics.38.224</pub-id><pub-id pub-id-type="pmid">11305038</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holl</surname><given-names>DC</given-names></name><name name-style="western"><surname>Volovici</surname><given-names>V</given-names></name><name name-style="western"><surname>Dirven</surname><given-names>CM</given-names></name><name name-style="western"><surname>Peul</surname><given-names>WC</given-names></name><name name-style="western"><surname>van Kooten</surname><given-names>F</given-names></name><name name-style="western"><surname>Jellema</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pathophysiology and nonsurgical treatment of chronic subdural hematoma: From past to present to future</article-title><source>World Neurosurg</source><year>2018</year><volume>116</volume><fpage>402</fpage><lpage>11.e2</lpage><pub-id pub-id-type="pmid">29772364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2018.05.037</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubbard</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Al Kasab</surname><given-names>S</given-names></name><name name-style="western"><surname>Porto</surname><given-names>GB</given-names></name><name name-style="western"><surname>Spiotta</surname><given-names>A</given-names></name></person-group><article-title>Chronic subdural hematoma recurrence due to contralateral neovascularization following middle meningeal artery embolization</article-title><source>Interv Neuroradiol</source><year>2021</year><volume>28</volume><fpage>639</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">34894830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15910199211065197</pub-id><pub-id pub-id-type="pmcid">PMC9706259</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jourdan</surname><given-names>E</given-names></name><name name-style="western"><surname>Dombret</surname><given-names>H</given-names></name><name name-style="western"><surname>Glaisner</surname><given-names>S</given-names></name><name name-style="western"><surname>Micl&#233;a</surname><given-names>JM</given-names></name><name name-style="western"><surname>Castaigne</surname><given-names>S</given-names></name><name name-style="western"><surname>Degos</surname><given-names>L</given-names></name></person-group><article-title>Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component</article-title><source>Br J Haematol</source><year>1995</year><volume>89</volume><fpage>527</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7734350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2141.1995.tb08358.x</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jumah</surname><given-names>F</given-names></name><name name-style="western"><surname>Osama</surname><given-names>M</given-names></name><name name-style="western"><surname>Islim</surname><given-names>AI</given-names></name><name name-style="western"><surname>Jumah</surname><given-names>A</given-names></name><name name-style="western"><surname>Patra</surname><given-names>DP</given-names></name><name name-style="western"><surname>Kosty</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of middle meningeal artery embolization in the management of refractory or chronic subdural hematomas: A systematic review and meta-analysis</article-title><source>Acta Neurochir (Wien)</source><year>2020</year><volume>162</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">31900658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00701-019-04161-3</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>RM</given-names></name><name name-style="western"><surname>Djulbegovic</surname><given-names>B</given-names></name><name name-style="western"><surname>Gernsheimer</surname><given-names>T</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>S</given-names></name><name name-style="western"><surname>Tinmouth</surname><given-names>AT</given-names></name><name name-style="western"><surname>Capocelli</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Platelet transfusion: A clinical practice guideline from the AABB</article-title><source>Ann Intern Med</source><year>2015</year><volume>162</volume><fpage>205</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">25383671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M14-1589</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>BS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JK</given-names></name><name name-style="western"><surname>Seo</surname><given-names>BR</given-names></name><name name-style="western"><surname>Moon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Clinical analysis of risk factors related to recurrent chronic subdural hematoma</article-title><source>J Korean Neurosurg Soc</source><year>2008</year><volume>43</volume><fpage>11</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19096538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3340/jkns.2008.43.1.11</pub-id><pub-id pub-id-type="pmcid">PMC2588154</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolluri</surname><given-names>SV</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>RD</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>KP</given-names></name><name name-style="western"><surname>Naidu</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>SC</given-names></name></person-group><article-title>Subdural hematoma secondary to immune thrombocytopenic purpura: Case report</article-title><source>Neurosurgery</source><year>1986</year><volume>19</volume><fpage>635</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3785604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/00006123-198610000-00023</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutty</surname><given-names>RK</given-names></name><name name-style="western"><surname>Peethambaran</surname><given-names>AK</given-names></name><name name-style="western"><surname>Sunilkumar</surname></name><name name-style="western"><surname>Anilkumar</surname><given-names>M</given-names></name></person-group><article-title>Conservative treatment of chronic subdural hematoma in HIV-associated thrombocytopenia with tranexamic acid</article-title><source>J Int Assoc Provid AIDS Care</source><year>2017</year><volume>16</volume><fpage>211</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">27909114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2325957416680294</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leader</surname><given-names>A</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>L</given-names></name><name name-style="western"><surname>Spectre</surname><given-names>G</given-names></name></person-group><article-title>Challenges and advances in managing thrombocytopenic cancer patients</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>1169</fpage><pub-id pub-id-type="pmid">33799591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10061169</pub-id><pub-id pub-id-type="pmcid">PMC8000983</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Srivatsan</surname><given-names>A</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>VM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SR</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>JK</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Middle meningeal artery embolization for chronic subdural hematoma in cancer patients with refractory thrombocytopenia</article-title><source>J Neurosurg</source><year>2021</year><volume>136</volume><fpage>1273</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">34624863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2021.5.JNS21109</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Link</surname><given-names>TW</given-names></name><name name-style="western"><surname>Boddu</surname><given-names>S</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>J</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>BI</given-names></name><name name-style="western"><surname>Lavi</surname><given-names>E</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>J</given-names></name></person-group><article-title>Middle meningeal artery embolization as treatment for chronic subdural hematoma: A case series</article-title><source>Operat Neurosurg</source><year>2018</year><volume>14</volume><fpage>556</fpage><lpage>62</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ons/opx154</pub-id><pub-id pub-id-type="pmid">28973653</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathews</surname><given-names>MS</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>ET</given-names></name></person-group><article-title>Spontaneous subdural hematoma in the setting of immune thrombocytopenia complicated by ischemic infarcts</article-title><source>Neuroradiol J</source><year>2007</year><volume>20</volume><fpage>224</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24299649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/197140090702000217</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moshayedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Liebeskind</surname><given-names>DS</given-names></name></person-group><article-title>Middle meningeal artery embolization in chronic subdural hematoma: Implications of pathophysiology in trial design</article-title><source>Front Neurol</source><year>2020</year><volume>11</volume><fpage>923</fpage><pub-id pub-id-type="pmid">32973670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00923</pub-id><pub-id pub-id-type="pmcid">PMC7481478</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mureb</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kondziolka</surname><given-names>D</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Raz</surname><given-names>E</given-names></name><name name-style="western"><surname>Nossek</surname><given-names>E</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>J</given-names></name><etal/></person-group><article-title>DynaCT enhancement of subdural membranes after middle meningeal artery embolization: Insights into pathophysiology</article-title><source>World Neurosurg</source><year>2020</year><volume>139</volume><fpage>e265</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">32298816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2020.03.188</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>HH</given-names></name><name name-style="western"><surname>Jang</surname><given-names>DK</given-names></name><name name-style="western"><surname>Cho</surname><given-names>BR</given-names></name></person-group><article-title>Complications and risk factors after digital subtraction angiography: 1-year single-center study</article-title><source>J Cerebrovasc Endovasc Neurosurg</source><year>2022</year><volume>24</volume><fpage>335</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">36153862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7461/jcen.2022.E2022.05.001</pub-id><pub-id pub-id-type="pmcid">PMC9829562</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nia</surname><given-names>AM</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>VM</given-names></name><name name-style="western"><surname>Lall</surname><given-names>RR</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P</given-names></name></person-group><article-title>Middle meningeal artery embolization for chronic subdural hematoma: A national database study of 191 patients in the United States</article-title><source>World Neurosurg</source><year>2021</year><volume>153</volume><fpage>e300</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">34214657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2021.06.101</pub-id><pub-id pub-id-type="pmcid">PMC8384691</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>NICE</collab></person-group><article-title>Overview Blood Transfusion Guidance</article-title><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/ng24" ext-link-type="uri">https://www.nice.org.uk/guidance/ng24</ext-link> [Last accessed on 2022 Mar 02]</comment></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauhala</surname><given-names>M</given-names></name><name name-style="western"><surname>Luoto</surname><given-names>TM</given-names></name><name name-style="western"><surname>Huhtala</surname><given-names>H</given-names></name><name name-style="western"><surname>Iverson</surname><given-names>GL</given-names></name><name name-style="western"><surname>Niskakangas</surname><given-names>T</given-names></name><name name-style="western"><surname>&#214;hman</surname><given-names>J</given-names></name><etal/></person-group><article-title>The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population</article-title><source>J Neurosurg</source><year>2019</year><volume>132</volume><fpage>1147</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">30901751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2018.12.JNS183035</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiffer</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bohlke</surname><given-names>K</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>M</given-names></name><name name-style="western"><surname>Hume</surname><given-names>H</given-names></name><name name-style="western"><surname>Magdalinski</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>283</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">29182495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.76.1734</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Karki</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name></person-group><article-title>Complications associated with diagnostic cerebral angiography: A retrospective analysis of 644 consecutive cerebral angiographic cases</article-title><source>Neurol India</source><year>2018</year><volume>66</volume><fpage>1154</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">30038108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0028-3886.237018</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirh</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>HR</given-names></name><name name-style="western"><surname>Park</surname><given-names>SQ</given-names></name></person-group><article-title>Usefulness of middle meningeal embolization to prevent recurrent spontaneous chronic subdural hemorrhage</article-title><source>J Cerebrovasc Endovasc Neurosurg</source><year>2018</year><volume>20</volume><fpage>40</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">30370239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7461/jcen.2018.20.1.40</pub-id><pub-id pub-id-type="pmcid">PMC6196131</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivatsan</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>A</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>FA</given-names></name><name name-style="western"><surname>Hafeez</surname><given-names>MU</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>VM</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Middle meningeal artery embolization for chronic subdural hematoma: Meta-analysis and systematic review</article-title><source>World Neurosurg</source><year>2019</year><volume>122</volume><fpage>613</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30481628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2018.11.167</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takase</surname><given-names>H</given-names></name><name name-style="western"><surname>Tatezuki</surname><given-names>J</given-names></name><name name-style="western"><surname>Ikegaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>D</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Therapeutic suggestions for chronic subdural hematoma associated with idiopathic thrombocytopenic purpura: A case report and literature review</article-title><source>NMC Case Rep J</source><year>2015</year><volume>2</volume><fpage>118</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">28663980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2176/nmccrj.2014-0209</pub-id><pub-id pub-id-type="pmcid">PMC5364897</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>K</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>S</given-names></name><name name-style="western"><surname>Nagamatsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Midorikawa</surname><given-names>H</given-names></name></person-group><article-title>Superselective angiographic findings of ipsilateral middle meningeal artery of chronic subdural hematoma in adults</article-title><source>No Shinkei Geka</source><year>1998</year><volume>26</volume><fpage>339</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">9592815</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaimori</surname><given-names>M</given-names></name></person-group><article-title>Histological study of vascular structure between the Dura mater and the outer membrane in chronic subdural hematoma in an adult</article-title><source>No Shinkei Geka</source><year>1999</year><volume>27</volume><fpage>431</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10363254</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yhim</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>NR</given-names></name><name name-style="western"><surname>Song</surname><given-names>EK</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yim</surname><given-names>CY</given-names></name></person-group><article-title>Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia</article-title><source>Int J Hematol</source><year>2012</year><volume>95</volume><fpage>585</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22403059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12185-012-1045-6</pub-id></element-citation></ref></ref-list><sec id="sec1-8"><title>Disclaimer</title><p>The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.</p></sec></back></article></pmc-articleset>